The AGNP-TDM Expert Group Consensus Guidelines: Focus on therapeutic monitoring of antidepressants

Dialogues in Clinical Neuroscience

Volumn 7, Issue 3, 2005, Pages 231-247

  Baumann, Pierre ^a,l   Ulrich, Sven ^b   Eckermann, Gabriel ^c   Gerlach, Manfred ^d   Kuss, Hans Joachim ^e   Laux, Gerd ^f   Müller Oerlinghausen, Bruno ^g,h   Rao, Marie Luise ⁱ   Riederer, Peter ^d   Zernig, Gerald ^j   Hiemke, Christoph ^k  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c Bezirkskrankenhaus Kaufbeuren   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f Bezirksklinikum Gabersee ^*  (Germany)

^g Drug Commission of the German Medical Association   (Germany)

^h Drug Commn of the Ger Med Assoc   (Germany)

ⁱ UNIVERSITY OF BONN   (Germany)

^j UNIVERSITY OF INNSBRUCK   (Austria)

^k JOHANNES GUTENBERG UNIVERSITY   (Germany)

^l DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

more..

Author keywords

Antidepressant; Consensus guidelines; Pharmacotherapy; Psychiatry; Therapeutic drug monitoring

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NORCLOMIPRAMINE; NORDOXEPIN; NORFLUOXETINE; NORSERTRALINE; NORTRIMIPRAMINE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG SURVEILLANCE PROGRAM; GENOTYPE; HUMAN; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG MONITORING; HUMANS;

EID: 24644466126     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (173)

1. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(suppl 4):1-45
2. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:5-43.
3. Donoghue J, Taylor DM. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs. 2000;13:365-383.
4. Hirschfeld RMA, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826-837.
5. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants-do they offer advantages over the SSRIs? CNS Drugs. 2001;15:941-954.
6. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000;61(suppl 2):13-19.
7. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry. 2001;34:119-127.
8. Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Br J Psychiatry. 2002;181:284-294.
9. Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry. 2001;62:221-224.
10. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
11. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
12. Åsberg M, Cronholm B, Sjöqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ. 1971;3:331-334.
13. Bertilsson L, Mellström B, Sjöqvist F, Mårtensson B, Åsberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet. 1981;i:560-561.
14. Task Force. Tricyclic antidepressants-blood level measurements and clinical outcome: an APA Task Force report. Am J Psychiatry. 1985;142:155-162.
15. Orsulak PJ. Therapeutic monitoring of antidepressant drugs-guidelines updated. Ther Drug Monit. 1989;11:497-507.
16. Linder MW, Keck PE, Jr. Standards of laboratory practice: antidepressant drug monitoring. Clin Chem. 1998;44:1073-1084.
17. Laux G, Riederer P (eds). Plasmaspiegel-bestimmung von Psychopharmaka: Therapeutisches Drug - Monitoring Versuch einer ersten Standortbestimmung. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH; 1992.
18. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
19. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002;41:453-470.
20. Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet. 1998;34:227-263.
21. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
22. Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19(suppl 1):23S-35S.
23. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
24. Meyer UA, Amrein R, Balant LP, et al. Antidepressants and drug-metabolizing enzymes-expert group report. Acta Psychiatr Scand. 1996;93:71-79.
25. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19:373-409.
26. Breyer-Pfaff U, Gaertner HJ, Baumann P. Antidepressiva-Pharmakologie, therapeutischer Einsatz und Klinik der Depressionen. 2nd ed. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH; 2005.
27. Marzo A, Balant LP. Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods. J Chromatogr B Biomed Appl. 1996;678:73-92.
28. Baumann P, Zullino DF, Eap CB. Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol. 2002;12:433-444.
29. Testa B. Drug metabolism. In: Wolff ME, ed. Burger's Medicinal Chemistry and Drug Discovery. 5th ed. New York, NY: John Wiley and Sons; 1995:129-180.
30. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmaco. 2001;21:500-515.
31. Burchell B. Transformation reactions: glucuronidation. In: Woolf TF, ed. Handbook of Drug Metabolism. New York, NY: Marcel Dekker; 1999:153-173.
32. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002;22:366-370.
33. Caccia S, Garattini S. Formation of active metabolites of psychotropic drugs: an updated review of their significance. Clin Pharmacokinet. 1990;18:434-459.
34. Eadie MJ. Formation of active metabolites of anticonvulsant drugs-a review of their pharmacokinetic and therapeutic significance. Clin Pharmacokinet. 1991;21:27-41.
35. Rudorfer MV, Potter WZ. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs. 1997;7:273-312.
36. Bertilsson L, Dahl ML, Dalen P, Al Shurbaji A. Molecular genetics of CYP 2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
37. Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest. 2003;33(suppl 2):17-22.
38. Murray M. P450 Enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet. 1992;23:132-146.
39. Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit. 2000;22:114-117.
40. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
41. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1-19.
42. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol. 1999;19:325-354.
43. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:3-27.
44. Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics. 2002;3:201-218.
45. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
46. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999;125:803-808.
47. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C_A polymorphism in intron I of the cytochrome P450 CYP 1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445-449.
48. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit. 1996;18:393-396.
49. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55(suppl 12):38-45.
50. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000;22:118-121.
51. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta. 2002;315:137-155.
52. Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine-implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry. 2003;36(suppl 3):S235-S243.
53. Eap CB, Jaquenoud Sirot E, Baumann P. Therapeutic monitoring of antidepressants in era of pharmacogenetics studies. Ther Drug Monit. 2004;26:152-155.
54. De Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol. 2003;6:57-72.
55. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
56. Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003;37:179-185.
57. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdrla P-glycoprotein gene disruption. Neuropsychopharmacology. 2000;22:380-387.
58. Perry PJ. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet. 1987;13:381-392.
59. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol. 1994;14:230-240.
60. Ulrich S, Läuter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet. 2002;41:853-876.
61. Balant-Gorgia EA, Balant LP. Therapeutic drug monitoring-relevance during the drug treatment of psychiatric disorders. CNS Drugs. 1995;4:432-453.
62. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders-clinical use and cost effectiveness. Clin Pharmacokinet. 1995;29:442-450.
63. Green M. A practical guide to analytical method validation. Anal Chem News Features. 1996:305-309.
64. Buick AR, Doig MV, Jeal SC, Land GS, Mcdowall RD. Method validation in the bioanalytical laboratory. J Pharm Biomed Anal. 1990;8:629-637.
65. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation-bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res. 1992;9:588-592.
66. Causon R. Validation of chromatographic methods in biomedical analysis viewpoint and discussion. J Chromatogr B. 1997;689:175-180.
67. de la Torre R, Ortuño J, Pascual JA, Gonzalez S, Ballesta J. Quantitative determination of tricyclic antidepressants and their metabolites in plasma by solid-phase extraction (bond-elute TCA) and separation by capillary gas chromatography with nitrogen-phosphorus detection. Ther Drug Monit. 1998;20:340-346.
68. Banger M, Hermes B, Härtter S, Hiemke C. Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography. Pharmacopsychiatry. 1997;30:128-132.
69. Kollroser M, Schober C. Simultaneous determination of seven tricyclic antidepressant drugs in human plasma by direct-injection HPLC-APCI-MSMS with an ion trap detector. Ther Drug Monit. 2002;24:537-544.
70. Veuthey JL, Souverain S, Rudaz S. Column-switching procedures for the analysis of drugs in biologic samples. Ther Drug Monit. 2004;26:161-166.
71. Simmons SA, Perry PJ, Rickert ED, Browne JL. Cost-benefit analysis of prospective pharmocokinetic dosing of nortriptyline in depressed inpatients. J Affect Disord. 1985;8:47-53.
72. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101:354-359.
73. Müller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36:98-104.
74. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996;60:522-534.
75. Chou WH, Yan FX, Barnhill J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20:246-251.
76. Veenstra DL, Higashi MK. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci. 2000;2:1-11.
77. Baumann P, Jonzier-Perey M, Koeb L, Le PK, Tinguely D, Schöpf J. Amitriptyline pharmacokinetics and clinical response. I. Free and total plasma amitriptyline and nortriptyline. Int Clin Psychopharmacol. 1986;1:89-101.
78. Jungkunz G, Kuss HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline-treated depressive patients. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:111-116.
79. Breyer-Pfaff U, Gaertner HJ, Kreuter F, Scharek G, Brinkschulte M, Wiatr R. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology. 1982;76:240-244.
80. Breyer-Pfaff U, Gaertner HJ, Giedke H. Plasma levels, psychophysiological variables, and clinical response to amitriptyline. Psychiatry Res. 1982;6:223-234.
81. Kupfer DJ, Hanin I, Spiker DG, Grau T, Coble P. Amitriptyline plasma levels and clinical response in primary depression. Clin Pharmacol Ther. 1977;22:904-911.
82. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16:307-314.
83. Baumann P, Nil R, Bertschy G, et al. A double-blind double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord. 1998;49:203-210.
84. Kramer Nielsen K, Brosen K, Gram LF, et al. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1992;43:405-411.
85. Danish University Antidepressant Group. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther. 1999;66:152-165.
86. Müller-Oerlinghausen B, Fahndrich E. The relationship between pharmacokinetic data and the clinical response in patients treated with maprotiline or clomipramine by intravenous infusion. Pharmacopsychiatry. 2002;18:100-101.
87. Burch JE, Raddats MA. Time course of plasma drug levels during once-daily oral administration of clomipramine. Psychopharmacology. 1982;77:344-347.
88. Friedel RO, Veith RC, Bloom V, Bielski RJ. Desipramine plasma levels and clinical response in depressed outpatients. Commun Psychopharmacol. 1979;3:81-87.
89. Amsterdam JD, Brunswick DJ, Winokur A, Rickels K. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Arch Gen Psychiatry. 1985;42:361-364.
90. Nelson JC, Jatlow Pl, Mazure C. Desipramine plasma levels and response in elderly melancholic patients. J Clin Psychopharmacol. 1985;5:217-220.
91. Maguire KP, Norman TR, Burrows GD, Davies B. Blood and plasma concentrations of dothiepin and its major metabolites and clinical response. J Affect Disord. 1982;4:41-48.
92. Ilett KF, Blythe TH, Hackett LP, Ong RTT, Tannenbaum DA, Clarke TMF. Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness. Ther Drug Monit. 1993;15:351-357.
93. Adler L, Hajak G, Lehmann K, et al. On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression-a placebo-controlled double-blind trial with doxepin. Pharmacopsychiatry. 1997;30:62-69.
94. Deuschle M, Härtter S, Hiemke C, Standhardt H, Heuser I. Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology. 1997;131:19-22.
95. Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol. 2001;21:432-439.
96. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology. 1996;128:421-425.
97. Bondolfi G, Lissner C, Kosel M, Eap CB, Baumann P. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacology. 2000;3:55-60.
98. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit. 2001;23:139-147.
99. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:963-969.
100. Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 1998;20:446-449.
101. Kasper S, Dötsch M, Kick H, Vieira A, Möller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol. 1993;3:13-21.
102. Gerstenberg G, Aoshima T, Fukasawa T, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology. 2003;167:443-448.
103. Reisby N, Gram LF, Bech P, et al. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology. 1977;54:263-272.
104. Gabris G, Baumann P, Jonzier-Perey M, Bosshart P, Woggon B, Kupfer A. N-Methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients. Biochem Pharmacol. 1985;34:409-410.
105. Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y. Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin? Hum Psychopharmacol Clin Exp. 1991;6:243-248.
106. Mihara K, Otani K, Tybring G, Dahl ML, Bertilsson L, Kaneko S. The CYP 2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol. 1997;17:467-471.
107. Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit. 1999;21:166-170.
108. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from remeron tablets. Hum Psychopharmacol. 1995;10:S97-S106.
109. Schoerlin MP, Mayersohn M, Korn A, Eggers H. Disposition kinetics of moclobemide, a monoamine oxidase A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther. 1987;42:395-404.
110. Lundmark J, Thomsen IS, Fjord-Larsen T, et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand. 1989;80(suppl 350):76-80.
111. Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51:278-287.
112. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;80(suppl 350):60-75.
113. Pellizzoni C, Poggesi I, Jorgensen NP, Edwards DMF, Paus E, Strolin Benedetti M. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos. 1996;17:623-633.
114. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
115. Axelson DA, Perel JM, Birmaher B, et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41:1037-1044.
116. Otani K, Tybring G, Mihara K, et al. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients. Eur J Clin Pharmacol. 1998;53:347-349.
117. Mihara K, Kondo T, Suzuki A, et al. Effects of genetic polymorphism of CYP 1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients. Pharmacol Toxicol. 2001;88:267-270.
118. Cournoyer G, De Montigny C, Ouellette J, et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol. 1987;7:385-393.
119. Eap CB, Bender S, Gastpar M, et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP 2D6-, CYP 2C19-and CYP 3A4/5-phenotyped patients. Ther Drug Monit. 2000;22:209-214.
120. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol. 1995;35:404-409.
121. Reis M, Lundmark J, Bjork H, Bengtsson F. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit. 2002;24:545-553.
122. Müller-Oerlinghausen B, Rüther E. Clinical profile and serum concentration of viloxazine as compared to amitriptyline. Pharmakopsychiatr Neuropsychopharmakol. 1979;12:321-337.
123. Pedersen OL, Gram LF, Kristensen CB, et al. Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol. 1982;23:513-521.
124. Preskorn S, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990;10:88-95.
125. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol. 1985;28:553-557.
126. Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit. 1996;18:111-117.
127. Jonasson B, Saldeen T. Citalopram in fatal poisoning cases. Forensic Sci Int. 2002;126:1-6.
128. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Clomipramine concentration as a predictor of delayed response: a naturalistic study. Eur J Clin Pharmacol. 1999;54:895-902.
129. Mavissakalian MR, Jones B, Olson S, Perel JM. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol. 1990;10:261-268.
130. McIntyre IM, King CV, Cordner SM, Drummer OH. Postmortem Clomipramine: therapeutic or toxic concentrations? J Forensic Sci. 1994;39:486-493.
131. Rodriguez de Ia Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit. 2001;23:435-440.
132. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry. 1992;53:160-162.
133. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet. 1994;27:307-330.
134. Montgomery SA, Montgomery DB, McAuley R, Rani SJ. Mianserin plasma levels and differential clinical response in endogenous and reactive depression. Acta Psychiatr Belg. 1978;78:798-812.
135. Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressants-a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand. 1997;96:94-100.
136. Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:461-474.
137. Velazquez C, Carlson A, Stokes KA, Leikin JB. Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001;43:342-344.
138. Fritze J, Laux G, Sofie E, et al. Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines. Psychopharmacology. 1989;99:252-256.
139. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit. 1995;17:39-46.
140. Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry. 1995;28:35-44.
141. Åsberg M, Cronholm B, Sjöqvist F, Tuck D. Correlation of subjective side effects with plasma concentrations of nortriptyline. BMJ. 1970;4:18-21.
142. Tasker TCG, Kaye CM, Zussman BD, Link CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand. 1989;80(suppl 350):152-155.
143. Ohman D, Norlander B, Peterson C, Bengtsson F. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC. Ther Drug Monit. 2001;23:27-34.
144. Milner DA, Hall M, Davis GG, Brissie RM, Robinson CA. Fatal multiple drug intoxication following acute sertraline use. J Anal Toxicol. 1998;22:545-548.
145. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants-cost implications and relevance to clinical practice. Clin Pharmacokinet. 1999;37:147-165.
146. Iwersen S, Schmoldt A. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. J Anal Toxicol. 1996;20:301-304.
147. Monteleone P, Gnocchi G, Delrio G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol. 1989;9:284-287.
148. Goeringer KE, Raymon L, Christian GD, Logan BK. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci. 2000;45:633-648.
149. Veefkind AH, Haffmans PMJ, Hoencamp E. Venlafaxine serum levels and CYP 2D6 genotype. Ther Drug Monit. 2000;22:202-208.
150. Levine B, Jenkins AJ, Queen M, Jufer R, Smialek JE. Distribution of venlafaxine in three postmortem cases. J Anal Toxicol. 1996;20:502-505.
151. Norman TR, Burrows GD, Davies BM, Maguire KP, Wurm JM. Viloxazine plasma concentrations and clinical response. J Affect Disord. 1980;2:157-164.
152. Altamura AC, Mauri MC, Guercetti G. Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:67-75.
153. Falcy M, Riboulet-Delmas G, Efthymiou ML. [Acute poisoning by viloxazine chlorhydrate taken by itself]. Encéphale. 1983;9:137-144.
154. McLeod DR, Hoehn-Saric R, Porges SW, Kowalski PA, Clark CM. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000;20:615-621.
155. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469.
156. Rasmussen BB, Broøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154.
157. Baumann P, Kahn JM. Les médicaments génériques: quels sont les problèmes et d'où viennent-ils? Med Hyg. 2003;61:879-884.
158. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother. 2001;35:281-284.
159. Meredith PA. Generic drugs-therapeutic equivalence. Drug Safety. 1996;15:233-242.
160. Tse G, Thompson D, Procyshyn RM. Generic clozapine: a cost-saving alternative to brand name clozapine? PharmacoEconomics. 2003;21:1-11.
161. American Academy of Pediatrics. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 2000;105:880-887.
162. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast-feeding. Am J Psychiatry. 2001;158:1001-1009.
163. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding. A review. J Clin Psychiatry. 2001;61:79-90.
164. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry. 1998;59(suppl 2):41-52.
165. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl 4):42-55.
166. European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on dose response information to support drug registration. 1995. Available at: www.emea.eu.int/pdfs/human/ich/037895en.pdf. Accessed 16 June 2005.
167. Bertilsson L, Dahl ML. Polymorphic drug oxidation-relevance to the treatment of psychiatric disorders. CNS Drugs. 1996;5:200-223.
168. Ensom MHH, Chang TKH, Patel P. Pharmacogenetics-the therapeutic drug monitoring of the future? Clin Pharmacokinet. 2001;40:783-802.
169. Vuille F, Amey M, Baumann P. Use of plasma level monitoring of antidepressants in clinical practice-towards an analysis of clinical utility. Pharmacopsychiatry. 1991;24:190-195.
170. Koutsilieri E, Scheller C, ter Meulen V, Riederer P. Monoamine oxidase inhibition and CNS immunodeficiency infection. Neurotoxicology. 2004;25:267-270.
171. Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP 2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438-452.
172. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs TDM "nouveau." Ther Drug Monit. 2004;26:145-151.
173. Bondy B, Zill P. Psychopharmacogenetics-a challenge for pharmacotherapy in psychiatry. World J Biol Psychiatry. 2001;2:178-183.